ClinicalTrials.gg
Not yet recruitingNCT07767942UNISHAPE-OSA-1Updated Nov 3, 2026

UBT251 Injection Phase Ⅲ Study (OSA-NPAP)

A Phase 3 interventional study of UBT251 and UBT251 in Obstructive Sleep Apnea, Obesity, sponsored by The United Bio-Technology (Hengqin) Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by The United Bio-Technology (Hengqin) Co., Ltd. (part of The United Laboratories International Holdings Limited) · Phase 3, Interventional, and Treatment

Updated Nov 3, 2026Start date movedGo to Updates ↓
Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The objective of this clinical trial is to evaluate the efficacy of investigational drug UBT251 in the treatment of moderate-to-severe obstructive sleep apnea (OSA) with obesity, as well as to assess its safety. The key research question is:

Does UBT251 reduce the Apnea-Hypopnea Index (AHI) in participants?

UBT251 will be compared with placebo (an inactive substance identical in appearance) to determine its efficacy in treating moderate-to-severe OSA.

Participants will:

Receive weekly subcutaneous injections of either UBT251 or placebo for a duration of 52 weeks

Undergo examinations and testing at protocol-specified visit windows

Have their AHI assessed following the 52-week treatment period

02

Conditions studied

  • Obstructive Sleep Apnea, Obesity

Keywords

  • obstructive sleep apnea
  • obesity
  • GLP-1
  • GIP
  • GCG
03

In context

Sleep Apnea, Obstructive

2,240 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

This study's planned enrollment of 150 is above the median of 52 across 1,472 interventional studies indexed under Sleep Apnea, Obstructive.

Browse Sleep Apnea, Obstructive studies →

Lead sponsor

The United Bio-Technology (Hengqin) Co., Ltd. is the lead sponsor of 13 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants aged 18 to 75 years inclusive at the time of signing the form.
  • Confirmed diagnosis of obstructive sleep apnea (OSA) based on the International Classification of Sleep Disorders, 3rd Edition, Text Revision (ICSD-3-TR) criteria, with a polysomnography (PSG) showing an Apnea-Hypopnea Index (AHI) ≥ 15 events/hour at screening.
  • Participants who are unwilling or unsuitable to receive positive airway pressure (PAP) therapy, and who have not received PAP therapy within 4 weeks prior to screening.
  • (BMI) ≥ 28 kg/m² at screening.
  • Weight has been stable for 3 months prior to screening (body weight change \< 5%) (based on self-report).
  • Participants of and their partners must have no plan for conception from screening until 6 months after completion of the trial, voluntarily use effective measures, and have no plan to donate sperm or oocytes within 6 months after trial completion.
  • Willingness to provide written informed consent and strictly comply with the protocol.

Exclusion criteria

Exclusion Criteria:

  • Known to the drug, its , or other drugs with similar pharmacological activity.
  • Use of any of the following within 3 months prior to screening:

    1. GLP-1 receptor agonists or similar drugs;
    2. biguanides, SGLT-2 inhibitors, DPP-4 inhibitors, or any other hypoglycemic agents;
    3. weight-influencing medications (including systemic , tricyclic antidepressants, antipsychotics, mood stabilizers);
    4. over-the-counter weight-loss drugs, prescription weight-loss drugs (e.g., orlistat), or lipolytic injections; stimulants, sedative-hypnotics, opioids, trazodone, or muscle relaxants;
    5. medications that may affect excessive daytime sleepiness assessment.
  • History or evidence of:

    1. Diagnosed with type 1 diabetes, type 2 diabetes, or other types of diabetes (except history of gestational diabetes);
    2. History of acute or chronic pancreatitis, or pancreatic surgery;
    3. History of symptomatic gallbladder disease within 1 year prior to screening;
    4. Personal or family history (first-degree relatives, i.e., parents, children, or siblings) of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2);
    5. Presence of endocrine diseases that may significantly affect body weight;
    6. History of bariatric surgery or planned weight-loss procedures (with specific exceptions for procedures >1 year prior);
    7. Previous history of depression, or Patient Health Questionnaire-9 (PHQ-9) score ≥ 15 at screening, or history of severe mental illness;
    8. positive C-SSRS for suicidal ideation/behavior;
    9. History of cardiovascular or cerebrovascular disease within 6 months;
    10. History or presence of severe retinal or macular lesions;
    11. History of sleep apnea surgery or major ENT surgery that may still affect breathing;
    12. History or presence at screening of clinically relevant medical conditions (other than OSA) or psychiatric disorders related to insomnia or excessive sleepiness;
    13. Receiving other active device therapies for OSA;
    14. Presence of other sleep disorders besides OSA;
    15. History or diagnosis of obesity hypoventilation syndrome or diurnal hypercapnia;
    16. Requirement for supplemental oxygen therapy;
    17. Severe craniofacial bony deformities or abnormalities significantly affecting the airway;
    18. Presence of gastrointestinal motility disorders, gastrointestinal diseases increasing post-dose risks, or history of major gastrointestinal surgery;
    19. within 5 years (except cured skin, cervical, or prostate in situ);
    20. Major surgery, severe trauma, or severe infection within 1 month;
    21. Concomitant diseases affecting participant safety, efficacy evaluation, or compliance.
  • Abnormal lab results:

    1. ≥6.5% or FPG ≥7.0 mmol/L;
    2. /AST ≥3× or total ≥1.5×ULN or \<60 mL/min/1.73m²;
    3. calcitonin ≥50 pg/mL;
    4. uncontrolled thyroid dysfunction or TI-RADS ≥4a nodules;
    5. fasting TG ≥5.6 mmol/L;
    6. amylase/lipase >2×ULN;
    7. >ULN;
    8. \<90 g/L;
    9. untreated hypertension (SBP ≥160 and/or DBP ≥100 mmHg);
    10. clinically significant abnormalities (2nd/3rd degree AV block, >470ms female/>450ms male, WPW, HR \<50 or >110);
    11. positive , , , or dual-positive syphilis;
    12. Physical examination, vital signs, laboratory tests, or other assessments showing clinically significant abnormalities that pose a significant risk to the participant or interfere with the evaluation of safety or PK results, rendering the participant unsuitable for the trial.
  • Participation in another interventional clinical trial within 3 months prior to screening.
  • Blood loss ≥400 mL or blood transfusion within 3 months prior to screening.
  • History of drug or alcohol abuse (female >7 or male >14 standard drinks/week).
  • Pregnant or lactating women.
  • Unable to tolerate venipuncture or history of needle/blood phobia.
  • Any other condition deemed unsuitable by the investigator.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    UBT251 Dose 1

    Participants will receive UBT251 subcutaneously (SC).

    Drug: UBT251

  • Experimental
    UBT251 Dose 2

    Participants will receive UBT251 subcutaneously (SC).

    Drug: UBT251

  • Placebo comparator
    Placebo

    Participants will receive placebo.

    Drug: Placebo

Interventions

  • DrugUBT251

    Administered SC

  • DrugUBT251

    Administered SC

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Change from baseline in the Apnea-Hypopnea Index (AHI)

    Time frame: Baseline, Week 52

Secondary outcomes

  1. Percentage change from baseline in AHI

    Time frame: Baseline, Week 52

  2. Percentage of participants with a reduction in AHI ≥ 50% from baseline

    Time frame: Baseline, Week 52

  3. Percentage of participants with an AHI < 5 events/hour or an AHI ≥ 5 and ≤ 14 events/hour with an Epworth Sleepiness Scale (ESS) score ≤ 10

    Time frame: Baseline, Week 52

  4. Percentage change from baseline in body weight

    Time frame: Baseline, Week 52

  5. Percentage of participants with a reduction in AHI ≥ 50% from baseline and a reduction in body weight ≥ 10% from baseline

    Time frame: Baseline, Week 20, Week 52

  6. Percentage change from baseline in the Sleep Apnea-Specific Hypoxia Burden (SASHB)

    Time frame: Baseline, Week 20, Week 52

  7. Change from baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep-Related Impairment Short Form 8a and PROMIS Sleep Disturbance Short Form 8b scores

    range: 0 to 100 for both scales; higher scores indicate worse sleep-related impairment and worse sleep disturbance, respectively

    Time frame: Baseline, Week 20, Week 52

  8. Percentage of participants with improvement in the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire

    range: 0 to 1; higher scores indicate better health-related quality of life

    Time frame: Baseline, Week 20, Week 52

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Sep 2028, 21 months later.

Of 25 phase 3 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 32. This study's planned 21 months is close to that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2026, on Nov 3, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2026
First posted
Aug 17, 2026
StartEst.
Dec 1, 2026was Sep 2026
Primary completionEst.
Sep 2028
CompletionEst.
Oct 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Sep 18, 2026→Dec 1, 2026
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Start date Sep 18, 2026→Dec 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07767942
Responsible party
Sponsor
First posted
Aug 17, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Nov 3, 2026

Study contacts

Linong Ji, MD
Contact
jiln@bjmu.edu.cn
+8610-88325372

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: UBT251

Start the discussion